

Haematologica
HAEMATOL/2019/220301
Version 3

Dose-adjusted EPOCH regimen as first-line treatment for
non-Hodgkin's lymphoma-associated hemophagocytic
lymphohistiocytosis: a single-arm, open-label, phase 2 trial

Jin-Hua Liang, Li Wang, Hua-Yuan Zhu, Jun Qian, Hui Liao, Jia-Zhu
Wu, Yi Xia, Wei Wu, Lei Cao, Lei Fan, Jian-Yong Li, and Wei Xu

Disclosures: All authors have nothing to disclose

Contributions: JYL and WX designed the experiment. JYL, WX, JQ and HL provided study materials or treated patients. JHL, LW, HYZ, JZW, YX, WW, LC and LF collected and assembled data. JHL, LW, HYZ, WX and JYL analysed and interpreted the data. JHL, LW, HYZ, LF, WX and JYL developed the tables and figures. JZW, YX, WW and LC did the literature search. JHL, LW, HYZ, WX and JYL wrote the report. All authors contributed to the interpretation of the data, critically revised the article throughout development for intellectual content, approved the final version and are accountable for the accuracy and integrity of the work.